On October 31, the 2020 Summit Forum on New Progress in CML Diagnosis and Treatment sponsored by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma") was successfully held in Shanghai. Academic experts in the field of hematological oncology gathered from all over the country to conduct in-depth discussions on the treatment strategy of chronic myeloid leukemia (CML), the status quo of CML treatment and the standardized management mode in China. Since its launch one year ago, Hansoh Xinfu (Flumatinib Mesylate Tablets) has attracted wide attention and won high praise for its good efficacy and safety in real-word clinical research. Mr. Lyu Aifeng, President of Hansoh Pharma, said in his speech that Hansoh Pharma will continue to innovate and make continuous efforts in advancing drug research and development in the field of hematologic oncology, promoting rational clinical use of drugs, and ensuring the maximum clinical benefits of CML patients.
Site of 2020 Summit Forum on New Progress in CML Diagnosis and Treatment
Flumatinib is "bi-directionally optimized" in terms of efficacy and safety, and the latest research data on its use as a first-line therapeutic agent for CML-CP were presented at the forum. The data come from Flumatinib China Phase III Clinical Research (FESTnd) (Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase 3, Randomized, Open-label, Multi-center FESTnd Study), which was recently published in Clinical Cancer Research, a top international clinical medical journal in the field of oncology, with an impact factor (IF) of 10.107.
Over the year since its launch, the clinical evidence-based data of flumatinib have received a lot of attention. The data from a real-world study of flumatinib involving 350 CML patients were shared at the forum, showing that flumatinib with good efficacy and safety has indeed provided a better treatment option for CML patients.
Hansoh Xinfu (Flumatinib Mesylate Tablets)
Focusing on innovation is the core element of Hansoh Pharma's high quality development. As a Chinese pharmaceutical enterprise with a 25-year history of development, Hansoh Pharma has developed a "Four-High" approach, namely, high intensity R&D investment, high focus on R&D, high quality R&D team, and high level R&D output, and has been ranked among the top 3 industrial enterprises in China's pharmaceutical R&D product line for many years in succession. It now has four Class 1 innovative drugs already on the market, covering solid tumors, hematological tumors, diabetes and anti-infection fields, and also nearly 20 innovative drugs still in various stages of clinical research. In the field of hematological oncology, which is a top priority of Hansoh Pharma, in addition to the innovative drug Hansoh Xinfu, Hansoh Pharma has launched a series of high-end first-time generic drugs in recent years, which covers a wide range of diseases and greatly improves the accessibility and affordability of drugs in this field. In the future, Hansoh Pharma will, as always, be committed to solving the unmet clinical needs in China's major fields of diseases through continuous innovation, to achieve the mission to create excellence in pharmaceuticals and enhance innovation in China.
